Editas Medicine, Inc.
BalancedEDIT·US·🇺🇸 US
47%buys·53%sales
929 transactions$12.5MTotal buys·195 buys
$94.7MTotal sells·220 sells
6565 insiders
Last: Dec 3, 2025
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Dec 3, 25 | Parison Amy | Sell | $991 | |
| Dec 3, 25 | O'Neill Gilmore Neil | Sell | $12K | |
| Dec 3, 25 | Burkly Linda | Sell | $2K | |
| Sep 3, 25 | O'Neill Gilmore Neil | Sell | $15K | |
| Sep 3, 25 | Parison Amy | Sell | $1K | |
| Sep 3, 25 | Burkly Linda | Sell | $2K | |
| Aug 7, 25 | Parison Amy | Sell | $2K | |
| Jul 31, 25 | Burkly Linda | Sell | $13K | |
| Jun 6, 25 | Hirsch Andrew | Grant | - | |
| Jun 6, 25 | Connaughton Bernadette | Grant | - |
Editas Medicine, Inc. is seeing coordinated insider selling. 3 insiders sold shares in the last 30 days, with total sell volume of $15K. Insider activity shows a balanced mix of buying and selling.
Editas Medicine, Inc. (EDIT) has recorded 929 insider operations, including 195 open-market purchases ($12.5M), 220 sales ($94.7M) and 514 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is balanced.
Insider activity at Editas Medicine, Inc. is sustained, with operations recorded in 8 of the last 12 months — a sign of regular regulatory filings.
Among the most active insiders are MULLEN JAMES C (CEO), Collins Cynthia (CEO) & Bosley Katrine (CEO), with respectively 370, 99, 62 transactions.
Across all 929 recorded transactions, the breakdown by type is: exercise (349, 38%), sales (220, 24%), buys (195, 21%), grant (142, 15%), other (23, 2%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Editas Medicine, Inc. has recorded 929 insider operations in total, including 195 open-market purchases ($12.5M), 220 sales ($94.7M) and 514 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on December 3, 2025.
Insiders at Editas Medicine, Inc. show balanced activity with 47% purchases and 53% sales. Total buy volume is $12.5M versus $94.7M in sales.
InsiderLens tracks 65 insiders at Editas Medicine, Inc. (EDIT). MULLEN JAMES C (CEO, 370 tx), Collins Cynthia (CEO, 99 tx), Bosley Katrine (CEO, 62 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for EDIT is neutral, based on a 47% buy ratio across 415 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Editas Medicine, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.